LPM3770164 sustained release tablet simulant

DRUG3 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Huntington DiseaseTardive DyskinesiaTardive Dyskinesia (TD)

Phase 1

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

CompletedNCT05238701

Luye Pharma Group Ltd.Huntington Disease, Tardive Dyskinesia

Start: 2022-02-25End: 2023-11-04Updated: 2024-01-29

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

CompletedNCT06216054

Luye Pharma Group Ltd.Huntington Disease, Tardive Dyskinesia

Start: 2023-12-19End: 2024-07-29Updated: 2024-12-12

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

RecruitingNCT06731868

Luye Pharma Group Ltd.Tardive Dyskinesia (TD)

Start: 2025-01-14End: 2025-10-31Target: 120Updated: 2025-01-22